Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantation

Iuliana Vaxman; Alissa Visram; Prashant Kapoor; Shaji Kumar; Angela Dispenzieri; Francis Buadi; David Dingli; Eli Muchtar; Wilson Gonsalves; Vincent Rajkumar; Taxiarchis Kourelis; Rahma Warsame; Martha Lacy; Morie A. Gertz

doi:10.1002/ajh.26023

Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantation

Iuliana Vaxman, Alissa Visram, Prashant Kapoor, Shaji Kumar, Angela Dispenzieri, Francis Buadi, David Dingli, Eli Muchtar, Wilson Gonsalves, Vincent Rajkumar, Taxiarchis Kourelis, Rahma Warsame, Martha Lacy, Morie A. Gertz^*

^*Corresponding author for this work

Clinical Departments

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	E35-E38
Journal	American Journal of Hematology
Volume	96
Issue number	1
DOIs	https://doi.org/10.1002/ajh.26023
State	Published - Jan 2021

Access to Document

10.1002/ajh.26023

Cite this

Vaxman, I., Visram, A., Kapoor, P., Kumar, S., Dispenzieri, A., Buadi, F., Dingli, D., Muchtar, E., Gonsalves, W., Rajkumar, V., Kourelis, T., Warsame, R., Lacy, M., & Gertz, M. A. (2021). Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantation. American Journal of Hematology, 96(1), E35-E38. https://doi.org/10.1002/ajh.26023

@article{cb4f5527b3ea4f5dbbc63e69ad2553c7,

title = "Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantation",

author = "Iuliana Vaxman and Alissa Visram and Prashant Kapoor and Shaji Kumar and Angela Dispenzieri and Francis Buadi and David Dingli and Eli Muchtar and Wilson Gonsalves and Vincent Rajkumar and Taxiarchis Kourelis and Rahma Warsame and Martha Lacy and Gertz, {Morie A.}",

note = "Funding Information: M.A.G. served as a consultant for Millennium Pharmaceuticals and received honoraria from Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Novartis, GlaxoSmithKline, Prothena, Ionis Pharmaceuticals, and Amgen. P.K. received research funding from Takeda Pharmaceuticals, Celgene, and Amgen. A.D. received research funding from Celgene, Millennium Pharmaceuticals, Pfizer, and Janssen and received a travel grant from Pfizer. M.L. received research funding from Celgene. S.K. served as a consultant for Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Janssen, and Bristol‐Myers Squibb and received research funding from Celgene, Millennium Pharmaceuticals, Novartis, Onyx Pharmaceuticals, AbbVie, Janssen, and Bristol‐Myers Squibb. The remaining authors declare no conflict of interest,. ",

year = "2021",

month = jan,

doi = "10.1002/ajh.26023",

language = "אנגלית",

volume = "96",

pages = "E35--E38",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "1",

}

TY - JOUR

T1 - Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantation

AU - Vaxman, Iuliana

AU - Visram, Alissa

AU - Kapoor, Prashant

AU - Kumar, Shaji

AU - Dispenzieri, Angela

AU - Buadi, Francis

AU - Dingli, David

AU - Muchtar, Eli

AU - Gonsalves, Wilson

AU - Rajkumar, Vincent

AU - Kourelis, Taxiarchis

AU - Warsame, Rahma

AU - Lacy, Martha

AU - Gertz, Morie A.

N1 - Funding Information: M.A.G. served as a consultant for Millennium Pharmaceuticals and received honoraria from Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Novartis, GlaxoSmithKline, Prothena, Ionis Pharmaceuticals, and Amgen. P.K. received research funding from Takeda Pharmaceuticals, Celgene, and Amgen. A.D. received research funding from Celgene, Millennium Pharmaceuticals, Pfizer, and Janssen and received a travel grant from Pfizer. M.L. received research funding from Celgene. S.K. served as a consultant for Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Janssen, and Bristol‐Myers Squibb and received research funding from Celgene, Millennium Pharmaceuticals, Novartis, Onyx Pharmaceuticals, AbbVie, Janssen, and Bristol‐Myers Squibb. The remaining authors declare no conflict of interest,.

PY - 2021/1

Y1 - 2021/1

UR - http://www.scopus.com/inward/record.url?scp=85096688147&partnerID=8YFLogxK

U2 - 10.1002/ajh.26023

DO - 10.1002/ajh.26023

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 33068019

AN - SCOPUS:85096688147

SN - 0361-8609

VL - 96

SP - E35-E38

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 1

ER -

Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantation

Access to Document

Other files and links

Cite this